PL2854788T3 - Zastosowanie witaminy K do zmniejszenia niepowodzenia przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu nerki - Google Patents

Zastosowanie witaminy K do zmniejszenia niepowodzenia przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu nerki

Info

Publication number
PL2854788T3
PL2854788T3 PL13729628.1T PL13729628T PL2854788T3 PL 2854788 T3 PL2854788 T3 PL 2854788T3 PL 13729628 T PL13729628 T PL 13729628T PL 2854788 T3 PL2854788 T3 PL 2854788T3
Authority
PL
Poland
Prior art keywords
vitamin
decrease
kidney transplantation
patient mortality
allograft failure
Prior art date
Application number
PL13729628.1T
Other languages
English (en)
Inventor
Cornelis Vermeer
Martin DE BORST
Original Assignee
Nattopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nattopharma As filed Critical Nattopharma As
Publication of PL2854788T3 publication Critical patent/PL2854788T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/10—Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
PL13729628.1T 2012-06-04 2013-06-04 Zastosowanie witaminy K do zmniejszenia niepowodzenia przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu nerki PL2854788T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170756.6A EP2671574A1 (en) 2012-06-04 2012-06-04 Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation
PCT/EP2013/061518 WO2013182578A1 (en) 2012-06-04 2013-06-04 Use of vitamin k to decrease allograft failure and patient mortality after organ transplantation

Publications (1)

Publication Number Publication Date
PL2854788T3 true PL2854788T3 (pl) 2025-02-24

Family

ID=48651994

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13729628.1T PL2854788T3 (pl) 2012-06-04 2013-06-04 Zastosowanie witaminy K do zmniejszenia niepowodzenia przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu nerki
PL13729629T PL2856152T3 (pl) 2012-06-04 2013-06-04 Nowe biomarkery do szacowania ryzyka niewydolności przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu narządu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL13729629T PL2856152T3 (pl) 2012-06-04 2013-06-04 Nowe biomarkery do szacowania ryzyka niewydolności przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu narządu

Country Status (11)

Country Link
US (2) US20150141386A1 (pl)
EP (3) EP2671574A1 (pl)
DK (1) DK2856152T3 (pl)
ES (1) ES2891249T3 (pl)
HR (1) HRP20211676T1 (pl)
HU (1) HUE056601T2 (pl)
LT (1) LT2856152T (pl)
PL (2) PL2854788T3 (pl)
PT (1) PT2856152T (pl)
SI (1) SI2856152T1 (pl)
WO (2) WO2013182579A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635478A (en) * 1989-09-18 1997-06-03 Yale University Use of calcitonin gene-related peptide to regulate immune response
WO2000008495A2 (en) * 1998-08-06 2000-02-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Antiproliferative naphthoquinones, derivatives, compositions, and uses thereof
US7700296B2 (en) 1999-07-04 2010-04-20 Mgp Diagnostics As Diagnostic assay for human Matrix Gla-protein and its use as a biomarker
AU6688700A (en) 1999-07-04 2001-01-22 Cardiovascular Research Institute Maastricht (Carim) Diagnostic assay for human matrix gla-protein and its use as a biomarker
DK1153548T3 (da) 2000-05-12 2007-09-10 Nattopharma Asa Levnedsmiddelprodukt, der indeholder vitamin k2
WO2004108748A2 (en) * 2002-09-24 2004-12-16 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
WO2005054503A2 (en) * 2003-12-03 2005-06-16 Novartis Ag Biomarkers for graft rejection
WO2005107731A1 (ja) * 2004-05-12 2005-11-17 Eisai R & D Management Co., Ltd. ビタミンk2を有効成分として含む治療剤
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
US20110300142A1 (en) * 2007-05-25 2011-12-08 Salford Leif G Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
WO2012012370A1 (en) * 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease

Also Published As

Publication number Publication date
PT2856152T (pt) 2021-09-29
ES2891249T3 (es) 2022-01-26
WO2013182578A1 (en) 2013-12-12
EP2854788A1 (en) 2015-04-08
US20150141386A1 (en) 2015-05-21
EP2856152B1 (en) 2021-08-04
HUE056601T2 (hu) 2022-02-28
EP2854788B1 (en) 2024-12-18
PL2856152T3 (pl) 2022-02-07
DK2856152T3 (da) 2021-11-01
HRP20211676T1 (hr) 2022-02-18
EP2671574A1 (en) 2013-12-11
US20150153352A1 (en) 2015-06-04
LT2856152T (lt) 2021-12-10
EP2856152A1 (en) 2015-04-08
WO2013182579A1 (en) 2013-12-12
EP2854788C0 (en) 2024-12-18
SI2856152T1 (sl) 2022-01-31

Similar Documents

Publication Publication Date Title
IL242804B (en) Pridopidine to reduce functional decline in Huntington's patients
GB2517609B (en) Artificial heart system
IL239353A0 (en) Continuous production unit and methods for using it
IL235285B (en) Heart valve prosthesis
SG11201504049VA (en) Compounds and their methods of use
ES1078818Y (es) Cápsula para preparar infusiones
HUE057701T2 (hu) Enzalutamid kiszerelési formái
IL241448A0 (en) Freezing viable human skin substitutes
EP2806811A4 (en) VERTEBRAL CONSTRUCTION
ZA201406082B (en) Use of ccr3-inhibitors
GB201310263D0 (en) Burial capsule
PT2879977T (pt) Cápsula para preparar bebidas
SG11201405110TA (en) Cell preparation including fat cell
GB201501016D0 (en) Preparation of 18F-fluciclovine
GB201215013D0 (en) Wheeled walking aid with sit to stand help
ZA201502709B (en) Oil formulations with thickeners
PL2854788T3 (pl) Zastosowanie witaminy K do zmniejszenia niepowodzenia przeszczepu allogenicznego i śmiertelności pacjentów po przeszczepieniu nerki
SG11201509640RA (en) Use of an isopropanol-containing solution to combat calciviridae
GB201316725D0 (en) Device to prevent loss of belongings
ES1077871Y (es) Cápsula para preparar infusiones
GB201200496D0 (en) Solar powered digital blood pressure monitor
GB201217445D0 (en) Preservation of cells
GB201202204D0 (en) Preservation of cells
IL233879A0 (en) Dry powdered dnase i preparations
IL233878A0 (en) Liquid dnase i preparations for inhalation